Denali Therapeutics (DNLI) Current Deferred Revenue (2017 - 2022)

Denali Therapeutics (DNLI) has 6 years of Current Deferred Revenue data on file, last reported at $290.1 million in Q4 2022.

• On a quarterly basis, Current Deferred Revenue rose 939.06% year-over-year to $290.1 million in Q4 2022; TTM through Dec 2022 was $290.1 million, a 939.06% increase from a year earlier, with the FY2022 full-year figure at $290.1 million, up 939.06% from the prior year.
• Current Deferred Revenue for Q4 2022 stood at $290.1 million, up from $23000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for DNLI reached as high as $290.1 million in Q4 2022 and fell as low as $23000.0 in Q3 2022.
• Historically, Current Deferred Revenue has averaged $31.2 million across 5 years, with a median of $18.5 million in 2019.
• Across the five-year window, Current Deferred Revenue surged 2548.51% in 2019 and slumped 98.26% in 2022, its largest moves.
• Year by year, Current Deferred Revenue stood at $11.4 million in 2018, then surged by 63.99% to $18.7 million in 2019, then gained by 6.27% to $19.9 million in 2020, then jumped by 40.18% to $27.9 million in 2021, then surged by 939.06% to $290.1 million in 2022.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $290.1 million in Q4 2022, $23000.0 in Q3 2022, and $27.9 million in Q4 2021.